UK markets open in 1 hour 48 minutes
NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,413.79 +206.66 (+1.14%) CRUDE OIL
79.12 +0.17 (+0.22%) GOLD FUTURES
2,316.40 +6.80 (+0.29%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,426.50 +1,719.25 (+3.76%)
Daiichi Sankyo Co Ltd (D4S.SG)
Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
At close: 08:01AM CEST
| Previous close | 31.23 |
| Open | 32.40 |
| Bid | 32.91 x 50000 |
| Ask | 33.96 x 50000 |
| Day's range | 32.40 - 32.40 |
| 52-week range | 22.55 - 34.30 |
| Volume | |
| Avg. volume | 190 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 29 Jul 2024 - 02 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
TOKYO & BASKING RIDGE, N.J., April 29, 2024--ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06
Yahoo FinanceAstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
ZacksAtossa (ATOS) Reports Positive Results From EVANGELINE Study
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.
© 2024 Yahoo. All rights reserved.